PICC Capital
人保资本
PICC Capital is the investment arm of the People's Insurance Company of China, appearing in elsewhere's corpus as a co-lead investor in major growth-stage tech deals. In September 2020 it joined Morningside and SoftBank Vision Fund 2 to co-lead XtalPi's $318.8 million Series C, then the largest funding round globally for an AI drug-discovery company . It reappeared in late 2021 co-leading Vastai Technologies' 1.6 billion RMB Series B-1 and B-2 alongside Alibaba, Matrix Partners China, and 5Y Capital, in a bet on high-end chip design . Elsewhere's corpus does not cover its broader mandate, AUM, or team structure beyond these disclosed deals.
AI-generated — may contain errors, please verify.
Coverage
2022, the Door Opens to the Future | 5Y News Monthly
The big news from last month.
五源资本·5Y News | Vastai Technologies Completes Two Consecutive Rounds of Series B-1 and B-2 Funding, Raising 1.6 Billion RMB
5Y Capital has been closely following the development of China's AI sector.
五源资本·Morningside-backed XtalPi raises over $300 million in new funding | Light Moments
5Y Capital has long been bullish on the application of computational science in the life sciences, hoping that the convergence of IT and biotechnology will soon usher human health into a new era.
五源资本·
